Actively Recruiting
Cardiac Magnetic Resonance-Clinical Prediction Model-Dilated Cardiomyopathy
Led by Shandong Provincial Hospital · Updated on 2026-04-14
2000
Participants Needed
1
Research Sites
887 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Dilated cardiomyopathy (DCM) is a common and serious heart disease characterized by left ventricular enlargement and impaired pumping function, with adverse prognosis (including heart failure, arrhythmia, heart-related hospitalization, and death) being a major concern for patients. Currently, a critical gap exists in accurately predicting which DCM patients are at high risk of these severe outcomes, limiting targeted clinical care. This observational, non-invasive study aims to develop and validate a clinical prediction model for early risk warning of adverse prognosis in DCM patients. The model integrates multi-parameter stress perfusion cardiac magnetic resonance (MP stress perfusion CMR)-a safe, high-resolution imaging technique that assesses cardiac structure, function, blood perfusion, and tissue damage under mild stress-and standard clinical data (e.g., age, gender, blood pressure, and routine heart test results). The model will be trained and tested using follow-up data from hundreds of DCM patients, with the analysis identifying patterns in CMR and clinical data associated with adverse outcomes. Once validated for accuracy, the model will provide doctors with personalized risk scores to prioritize care for high-risk patients (e.g., early intervention, close monitoring) and avoid over-treatment for lower-risk individuals. Beyond clinical application, the study will enhance understanding of DCM progression, laying the groundwork for improved diagnostic tools, more effective treatments, and better strategies to prevent DCM-related complications, ultimately improving patient quality of life and reducing mortality.
CONDITIONS
Official Title
Cardiac Magnetic Resonance-Clinical Prediction Model-Dilated Cardiomyopathy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Elevated left ventricular end-diastolic volume indexed to body surface area
- Reduced left ventricular ejection fraction compared to published age- and gender-specific reference values
You will not qualify if you...
- Significant coronary artery disease with 50% or greater stenosis in a major coronary artery
- Presence of infiltrative disease
- Presence of valvular cardiomyopathy
- Presence of arrhythmogenic cardiomyopathy
- Presence of congenital heart disease
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Jinan central hospital
Jinan, Shandong, China
Actively Recruiting
Research Team
W
Wenxian Wang, Dr
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here